Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CTMX | CytomX Therapeutics Inc

Index- P/E- EPS (ttm)-0.55 Insider Own2.02% Shs Outstand66.23M Perf Week-6.67%
Market Cap84.13M Forward P/E- EPS next Y-0.82 Insider Trans-1.70% Shs Float65.42M Perf Month-13.70%
Income-36.47M PEG- EPS next Q-0.19 Inst Own51.16% Short Float / Ratio3.31% / 7.94 Perf Quarter-10.64%
Sales85.26M P/S0.99 EPS this Y69.21% Inst Trans-19.56% Short Interest2.17M Perf Half Y-29.61%
Book/sh-1.27 P/B- EPS next Y-76.27% ROA-15.54% Target Price2.49 Perf Year-11.89%
Cash/sh2.71 P/C0.47 EPS next 5Y-0.90% ROE-4417.92% 52W Range1.17 - 3.02 Perf YTD-21.25%
Dividend- P/FCF- EPS past 5Y-5.43% ROI- 52W High-58.28% Beta0.68
Dividend %- Quick Ratio1.33 Sales past 5Y6.79% Gross Margin92.96% 52W Low7.69% ATR0.06
Employees116 Current Ratio1.33 Sales Q/Q36.11% Oper. Margin-40.76% RSI (14)23.29 Volatility4.61% 4.10%
OptionableYes Debt/Eq- EPS Q/Q95.58% Profit Margin-42.77% Rel Volume0.27 Prev Close1.26
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume272.93K Price1.26
Recom3.11 SMA20-9.45% SMA50-18.96% SMA200-30.70% Volume73,037 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-14-22Downgrade BMO Capital Markets Outperform → Market Perform $3 → $2.60
Jul-07-22Downgrade Wedbush Outperform → Neutral $6 → $2
Jul-07-22Downgrade Piper Sandler Overweight → Neutral $10 → $1.50
Jul-07-22Downgrade Mizuho Buy → Neutral $16 → $4
Jul-07-22Downgrade Jefferies Buy → Hold $12 → $2
Jun-24-22Initiated BMO Capital Markets Outperform $9
Jan-18-22Upgrade Barclays Underweight → Overweight $7
Nov-15-21Initiated BTIG Research Buy $16
May-28-21Downgrade Barclays Equal Weight → Underweight $9 → $7
Mar-29-21Initiated JP Morgan Overweight $14
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:15PM Loading…
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
May-09-23 05:35PM
04:26PM Loading…
May-05-23 06:34AM
May-01-23 04:01PM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
06:07AM Loading…
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
Jan-05-23 05:11PM
Dec-22-22 05:00PM
Dec-20-22 05:00PM
Dec-07-22 04:30PM
Nov-23-22 12:18PM
Nov-18-22 01:18PM
Nov-17-22 11:14AM
Nov-08-22 05:35PM
Nov-07-22 04:15PM
Nov-02-22 04:15PM
Nov-01-22 08:00AM
Oct-27-22 05:15PM
Sep-13-22 08:42AM
Sep-12-22 08:00AM
Sep-07-22 06:05PM
Sep-01-22 10:17AM
Aug-05-22 08:30AM
Aug-04-22 05:45PM
Aug-03-22 08:00AM
Aug-01-22 10:01AM
Jul-28-22 10:02AM
Jul-15-22 10:50AM
Jul-14-22 06:05AM
Jul-13-22 04:05PM
Jul-07-22 06:15AM
Jul-06-22 04:05PM
Jun-27-22 08:33AM
Jun-16-22 08:00AM
Jun-01-22 08:00AM
May-26-22 08:00AM
May-07-22 08:11AM
May-06-22 10:30PM
May-05-22 06:25PM
Apr-28-22 08:00AM
Apr-14-22 04:15PM
Apr-06-22 06:47AM
Mar-23-22 04:15PM
Mar-17-22 08:00AM
Mar-02-22 01:00AM
Mar-01-22 05:45PM
Feb-28-22 05:15PM
Feb-22-22 08:00AM
Feb-16-22 08:00AM
Feb-07-22 09:00AM
Feb-05-22 08:05AM
Jan-26-22 08:15AM
Jan-20-22 10:41AM
Jan-19-22 08:00AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.CEOSep 22Sale1.3014,60118,987430,755Sep 22 07:13 PM
ROWLAND LLOYD AGeneral CounselSep 22Sale1.305,4867,13580,609Sep 22 07:12 PM
BELVIN MARCIASVP, Chief Scientific OfficerSep 22Sale1.304,1195,356147,951Sep 22 07:16 PM
Landau Jeffrey BChief Business OfficerSep 22Sale1.304,1195,35676,379Sep 22 07:15 PM
McCarthy Sean A.CEOMay 19Option Exercise1.5716,53526,041405,356May 23 04:52 PM
Jones Elaine VDirectorMar 29Buy1.555,0007,7505,142Mar 31 07:56 PM
McCarthy Sean A.CEOMar 16Sale1.887,12113,391388,821Mar 20 06:43 PM
Peterson Amy C.EVP, Chief Development OfficerMar 16Sale1.984,2578,42558,433Mar 20 06:43 PM
ROWLAND LLOYD AGeneral CounselMar 16Sale1.982,0374,03171,095Mar 20 06:43 PM
Campoy CarlosChief Financial OfficerMar 16Sale1.981,7483,45938,224Mar 20 06:43 PM
Landau Jeffrey BChief Financial OfficerMar 16Sale1.981,4772,92369,248Mar 20 06:43 PM
Ogden ChristopherSVP, Finance and AccountingMar 16Sale1.985161,02137,772Mar 20 06:43 PM